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Abstract
Background
HIV infection increases cardiovascular risk. Coronary artery calcification (CAC) and mitral
annular calcification (MAC) identify patients at risk for cardiovascular disease (CVD). The
purpose of this study was to examine the association between MAC, CAC and mortality in
HIV-infected individuals.
Methods and Results
We studied 152 asymptomatic HIV-infected individuals with transthoracic echocardiogra-
phy (TTE) and computed tomography (CT). MAC was identified on TTE using standardized
criteria. Presence of CAC, CAC score and CAC percentiles were determined using the
modified Agatston criteria. Mortality data was obtained from the Social Security and
National Death Indices (SSDI/NDI). The median age was 49 years; 87% were male. The
median duration of HIV was 16 years; 84% took antiretroviral therapy; 64% had an unde-
tectable viral load. CVD risk factors included hypertension (35%), smoking (62%) and dysli-
pidemia (35%). Twenty-five percent of individuals had MAC, and 42% had CAC. Over a
median follow-up of 8 years, 11 subjects died. Subjects with CAC had significantly higher
mortality compared to those with MAC only or no MAC. The Harrell’s C-statistic of CAC was
0.66 and increased to 0.75 when MAC was added (p = 0.05). MAC, prior CVD, age and HIV
viral load were independently associated with higher age- and gender-adjusted CAC per-
centiles in an adjusted model (p < 0.05 for all).
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Conclusion
In HIV patients, the presence of MAC, traditional risk factors and HIV viral load were inde-
pendently associated with CAC. Presence of CAC and MACmay be useful in identifying
HIV-infected individuals at higher risk for death.
Background
Approximately 1.3 million HIV-positive adults are living in the United States and 34 million
HIV-infected individuals are living world-wide [1]. Since the advent of highly active antiretro-
viral therapy (HAART) in the mid to late 1990s, HIV-associated morbidity and mortality have
decreased substantially [2]. However, despite these advances in treatment, HIV-infected indi-
viduals continue have a shorter life expectancy when compared to uninfected controls [3,4]. In
the United States, the annual number of HIV-associated deaths fell from greater than 50,000
per year to less than 25,000 per year between 1993 and 2000, but has remained relatively
unchanged since this time [5]. This reduced life expectancy is thought to be largely secondary
to non-AIDS conditions, which now account for the majority of deaths in HIV [6]. Of particu-
lar concern, HIV-infected patients are at increased risk for cardiovascular disease, though the
mechanism is not completely understood [7–9]. HIV-infected patients have significantly
higher rates of myocardial infarction compared to controls, even in the setting of treated and
suppressed HIV disease [10]. In addition, individuals with HIV who are hospitalized for myo-
cardial infarction have higher in-hospital mortality as compared to uninfected individuals [11].
HIV patients also have higher rates of coronary artery calcification and systemic arterial calcifi-
cation than non-infected controls, which may reflect accelerated vascular aging [12]. Finally,
our group previously reported that HIV-infected individuals have substantially higher rates of
sudden cardiac death in comparison to uninfected individuals [13].
Mitral annular calcification (MAC) is a degenerative process involving the mitral valve
annulus, and is typically associated with older age [14]. MAC has been described in the setting
of various disease processes including systemic hypertension, aortic stenosis, hypertrophic
obstructive cardiomyopathy, mitral valve prolapse, and diseases of abnormal calcium and
phosphorus metabolism such as chronic kidney disease (CKD) or secondary hyperparathy-
roidism [14]. The presence of MAC closely correlates with systemic atherosclerosis [15,16], as
well as the prevalence and severity of coronary artery disease [14,17,18]. MAC is an indepen-
dent predictor of major cardiovascular events and mortality [19–26]. While these associations
have been described in the general population, the clinical significance of MAC among HIV-
infected individuals remains unclear.
Coronary artery calcification (CAC), identified on electron-beam computed tomography
(EBCT), is an established technique for identifying patients with, or at risk for coronary artery
disease [27]. The presence of CAC has proven to be predictive of cardiovascular disease, car-
diovascular mortality, and all-cause mortality in both symptomatic and asymptomatic individ-
uals [28–30]. Conversely, the absence of CAC on EBCT predicts excellent 10-year survival
[31]. The purpose of this study was to examine the association between MAC and CAC, and to
characterize their predictive value for mortality among asymptomatic HIV-infected
individuals.
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adherence to PLOS ONE policies on sharing data
and materials.
Methods
Study Design
We studied 152 HIV-infected individuals who underwent both Transthoracic Echocardiogram
(TTE), and CAC Protocol External Beam Computed Tomography (CT) study between 11/1/
2004 and 11/1/2012. The HIV-infected individuals were enrolled in an outpatient HIV-cohort
in San Francisco called the Study of the Consequences of the Protease Inhibitor Era (SCOPE).
Patients were seen in follow-up as part of the SCOPE study every four months.
Patient Selection
The SCOPE cohort included patients who can be categorized as: (1) untreated HIV-infected
patients, including a subset of individuals with undetectable HIV RNA levels, commonly
referred to as elite controllers, (2) patients on HAART who have detectable viremia, and (3)
treated patients who have achieved full virologic suppression. SCOPE patients are followed
longitudinally and are well characterized with regards to their HIV status, metabolic profiles
and cardiovascular risk factors. All patients who had at least one TTE and one CAC-protocol
CT scan between 11/1/2004 and 11/1/2012 were included in the initial analysis. Patients were
not preselected for cardiovascular risk factors or symptoms. Exclusion criteria included poor
study quality that precluded the interpretation of any one of the aforementioned studies and
individuals who could not obtain a CT scan due to renal disease (defined as estimated glomeru-
lar filtration rate< 60 mL/min), atrial fibrillation, or a history of prior CT scan contrast allergy.
The University of California, San Francisco Committee on Human Research approved this
study, and all patients provided written informed consent prior to enrollment.
Risk Factor Assessment
At the time of enrollment, each patient completed a standardized questionnaire, and a detailed
interview to compile sociodemographic characteristics, HIV disease history, presence of co-
morbid conditions, health-related behaviors, medication exposures, and family history. Addi-
tionally, fasting serum measurements of glucose, HDL cholesterol, LDL cholesterol, total cho-
lesterol, triglycerides, lipoprotein (a), high-sensitivity C-reactive protein, creatinine, CD4
count, and HIV viral load were obtained at the clinical laboratories of San Francisco General
Hospital. Standardized waist and hip measurements were obtained, and each patient was
assessed for changes in fat distribution.
MACMeasurements
Standard two-dimensional (2D) echocardiography recordings were obtained in the parasternal,
apical and subcostal views. M-mode recordings were performed in the parasternal long axis
and apical four chamber views (GE Vivid 7, GE Healthcare, Milwaukee, Wisconsin). Raw data
images were all interpreted off line (GE ECHOPac PC software) by a cardiologist (D.L.) to
determine the presence or absence of MAC. The cardiologist interpreting the echocardiograms
was blinded to all clinical information about the subjects. MAC was defined as the presence of
an abnormally echo-dense area visualized throughout systole and diastole, distinguishable
from the posterior mitral valve leaflet, located anterior and parallel to the posterior left ventric-
ular wall, and visualized in at least two views (e.g. parasternal long axis view and apical four
chamber view) (Fig 1A and 1B;Fig 2A and 2B). These diagnostic criteria are consistent with
those used in previous studies [15,23,26]. If MAC was present using these criteria, three mea-
surements from consecutive beats were taken in the parasternal long axis and apical four cham-
ber views using the caliper tool, following a pre-specified protocol (Figs 3 and 4).
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Fig 1. (A-B). MACwas defined as an echodense area visualized throughout systole and diastole,
distinguishable from the posterior mitral valve leaflet, located anterior and parallel to the posterior left
ventricular wall, seen here in the parasternal long axis view during diastole (A) and systole (B).
Abbreviations: Right Ventricle (RV), Left Ventricle (LV), Aorta (Ao), Mitral Annular Calcification (MAC), Left
Atrium (LA).
doi:10.1371/journal.pone.0130592.g001
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Fig 2. (A-B): MACwas defined as an echodense area visualized throughout systole and diastole,
distinguishable from the posterior mitral valve leaflet, located anterior and parallel to the posterior left
ventricular wall, seen here in the apical four chamber view during diastole (A) and systole (B).
Abbreviations: Right Ventricle (RV), Left Ventricle (LV), Mitral Annular Calcification (MAC), Left Atrium (LA),
Right Atrium (RA).
doi:10.1371/journal.pone.0130592.g002
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Coronary Calcium Measurements
Patients underwent CT imaging using a General Electric Light Speed\ 64-multi detector CT
(GE Healthcare, Milwaukee, Wisconsin). Following the Agatston protocol, images were
obtained in 2.5mm slices with no gap. Prospective cardiac gating was used to minimize motion
artifact. Post-processing was performed in a dedicated work-station (Advanced Workstation
Version 4.4, GE Healthcare, Milwaukee, Wisconsin). The detection of coronary calcium and
quantitative calcium scores were calculated according to previously described methods (see
Figs 5 and 6) [32]. A single cardiac radiologist (K.O.) performed the post-processing and inter-
pretation of the scans and was blinded to all clinical characteristics of the subjects.
Mortality Data
All mortality data were obtained from quarterly query of the National Death Index (NDI) and
Social Security Death Index (SSDI). If subjects were not found within one of these two indices,
they were presumed to be alive at the time of query.
Statistical Analyses
Differences between the groups were assessed using the Student’s t-test. For continuous vari-
ables with markedly non-normal distributions, the Wilcoxon rank sum test was used. Categori-
cal variables were compared with the Pearson’s χ2 test. Spearman rank correlation summarized
Fig 3. M-modemeasurement of MAC in the parasternal long axis view. Abbreviations: Mitral Annular Calcification (MAC).
doi:10.1371/journal.pone.0130592.g003
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associations between continuous variables. Multivariable linear regression analyses were per-
formed to find independent predictors of increased age- and gender-adjusted CAC percentiles.
Variables included in the model were age; gender; race; HIV-disease duration; CD4 count;
CD4-nadir; HIV viral-load; history of HAART exposure; history of hepatitis C infection;
hypertension; dyslipidemia; family history of coronary artery disease; tobacco pack-years; dia-
betes mellitus; the presence of MAC; prior CVD; current intravenous drug use and history of
intravenous drug use. Survival curves were generated by the method of Kaplan and Meier and
the Harrell’s C-statistic log rank test compared survival between groups. All tests were per-
formed using a two-tailed level of significance of p< 0.05, using STATA software (StataCorp
LP, College Station, Texas).
Results
Baseline Characteristics (entire cohort)
One-hundred fifty-two patients were enrolled in the study. Subjects’ median age was 50 years
(Interquartile Range (IQR) 44 to 55 years). One hundred thirty two subjects (86.8%) were
male. The median duration of HIV infection was 16 years (IQR 11 to 19 years), 127 subjects
were on antiretroviral therapy (83.7%), and 97 subjects (64%) had an undetectable viral load.
CVD risk factors included hypertension (35%), smoking (62%) and dyslipidemia (35%). Base-
line characteristics for the cohort are displayed in Table 1.
Fig 4. M-modemeasurement of MAC in the apical four chamber view.MAC—Mitral annular calcification; cm—centimeters. Abbreviations: Mitral Annular
Calcification (MAC).
doi:10.1371/journal.pone.0130592.g004
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HIV-infected individuals with MAC
Thirty-eight (25%) of the 152 subjects had evidence of MAC on echocardiography. Baseline
characteristics for subjects with and without MAC are shown in Table 2. There was no signifi-
cant difference between the groups with regards to traditional cardiovascular risk factors
(Table 2), except for family history of cardiovascular disease (CVD). Eight percent of HIV-
infected individuals with MAC reported a family history of CVD, whereas 26% of those with-
out evidence of MAC had a family history of CVD (p = 0.02). Median Body Mass Index (BMI)
did not differ between the groups, and baseline creatinine levels were similar as well. There was
Fig 5. CAC EBCT of a subject with CAC score of 0. Abbreviations: Coronary artery calcium (CAC), External beam computed tomography (EBCT).
doi:10.1371/journal.pone.0130592.g005
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no difference in duration of HIV infections (16 years IQR 10 to 19 vs. 16 years, IQR 11 to 19,
p = 0.99), or in median HIV RNA level between the groups (75 copies/mL, IQR 75 to 5138 vs.
75 copies/mL, IQR 75 to 221, p = 0.07). Similarly, there was no significant difference in median
CD4 count, median CD4 nadir, history of opportunistic infection, or duration of HAART use
(p> 0.05 for all, Table 2). Current intravenous drug use was more common in the MAC group
than in subjects without MAC (11% vs. 3%, p = 0.04); however, history of intravenous drug use
did not differ between the groups (21% vs. 17%, p = 0.54), and there was no difference in Hepa-
titis C infection between the two groups.
Fig 6. CAC EBCT of a subject with detectable CAC. Abbreviations: Coronary artery calcium (CAC), External beam computed tomography (EBCT).
doi:10.1371/journal.pone.0130592.g006
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Comparison of HIV-infected Subjects with and without CAC
Forty-two percent of the cohort had evidence of CAC on CT. Baseline characteristics for the
patients who had CAC are shown in Table 3. Subjects who had CAC did not differ from those
who did not have CAC with regards to gender, prevalence of hypertension, diabetes mellitus,
history of MI, tobacco use or BMI. However, subjects with CAC were older (median age 53
years, IQR 48 to 59 vs. 46.5 years, IQR 42 to 51 years, p< 0.0001), had a higher rates of dyslipi-
demia (48% vs. 25%, p< 0.01) and coronary artery disease (16% vs. 2%, p< 0.01) when com-
pared to subjects without CAC. HIV-disease characteristics including duration of HIV disease,
HIV RNA, CD4 count, CD4 nadir, history of opportunistic infection, history of HAART use,
duration of protease inhibitors, current abacavir use, and duration of HAART therapy did not
differ between subjects with or without CAC. There was no difference in the prevalence of cur-
rent or past intravenous drug use, and no difference in the prevalence of Hepatitis C viral infec-
tion between the two groups.
Table 1. Baseline Characteristics—Entire Study Cohort.
Age (median years, IQR) 50 (IQR 44 to 55)
Female 20 (13%)
Hypertension 56(37%)
Dyslipidemia 53 (35%)
Diabetes Mellitus 15 (10%)
CAD 12 (8%)
History of MI 5 (3%)
Tobacco use 94 (62%)
Tobacco Pack-years (median pack-years, IQR) 5.7 (IQR 0 to 20.75)
Family History of CAD 33 (22%)
BMI (median BMI in kg/m2, IQR) 25.79 (IQR 23.33 to 29.28)
Baseline Creatinine (median mg/dL, IQR) 1.0 (IQR 0.88 to 1.13)
HIV duration (median years since diagnosis, IQR) 16 (IQR 11 to 19)
HIV RNA Level (median copies/mL, IQR) 75 (IQR 75 to 444)
CD4 Count (median cell/mL, IQR) 464 (IQR 288 to 658)
CD4 Count Nadir (median cell/mL, IQR) 120 (IQR 35 to 295)
History of OI 63 (41%)
History of HAART use 127 (84%)
HAART Duration (median years, IQR) 5.79 (IQR 0.75 to 7.83)
IVDU (current) 7 (5%)
IVDU (ever) 27 (18%)
HCV Infection 36 (24%)
CAC present 64 (42%)
MAC present 38 (25%)
MAC and CAC present 22 (14%)
Age- and Gender-adjusted CAC percentile (median percentile, IQR) 0.0 (IQR 0.0 to 62.5%)
Abbreviations: Interquartile Range (IQR), Coronary Artery Disease (CAD), Myocardial Infarction (MI),
Human Immunodeficiency Virus (HIV), Human Immunodeficiency Virus Ribonucleic Acid Level (HIV RNA),
Cluster of Differentiation 4 cells (CD4), Opportunistic Infection (OI), Highly Active Anti-Retroviral Therapy
(HAART), Intravenous Drug-Use (IVDU), Hepatitis C Viral Infection (HCV), Coronary Artery Calcification
(CAC), Mitral Annular Calcification (MAC)
doi:10.1371/journal.pone.0130592.t001
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MAC and Coronary Calcium
The presence of MAC closely correlated with the presence of CAC, however, this trend did not
reach statistical significance (OR 2.04, 95% CI 0.97 to 4.29, p = 0.06). The presence of MAC
was associated with higher CAC scores. Namely, those with MAC had a median CAC score of
14.2 (IQR 0 to 150) versus a score of 0 (IQR 0 to 22) among those without MAC (p = 0.03).
The presence of MAC was also associated with higher age- and gender-adjusted CAC percen-
tiles (44% IQR 0 to 90% in MAC group vs. 0% IQR 0 to 40% in those without MAC, p< 0.001,
Table 2. Baseline Characteristics—HIV-Subjects with MAC vs. those without MAC.
MAC (n = 38) No MAC (n = 114) P value
Age (median years, IQR) 47.5 (IQR 42 to
54.25)
50 (IQR 44 to 55.25) 0.14§
Female (n, %) 3 (8%) 17 (15%) 0.30‡
Hypertension (n, %) 10 (26%) 46 (40%) 0.12‡
Dyslipidemia (n, %) 13 (34%) 40 (35%) 0.99‡
Diabetes Mellitus (n, %) 4 (11%) 11 (10%) 0.88‡
CAD (n, %) 5 (13%) 7 (6%) 0.17‡
History of MI (n, %) 1 (3%) 4 (4%) 0.79‡
Tobacco use (n, %) 22 (58%) 72 (63%) 0.56‡
Tobacco Pack-years (median Pack-years, IQR) 7.75 (IQR 0 to
20.75)
5.2 (IQR 0 to 21.38) 0.96§
Family History of CAD (n, %) 3 (8%) 30 (26%) 0.02‡
BMI (median kg/m2, IQR) 24.73 (IQR 22.83 to
27.42)
26.18 (IQR 23.75 to
30.17)
0.10§
Baseline Creatinine (median mg/dL, IQR) 1.0 (IQR 0.83 to
1.16)
0.99 (IQR 0.90 to
1.10)
0.97§
HIV duration (median years since diagnosis, IQR) 16 (IQR 10 to 19) 16 (IQR 11 to 19) 0.99§
HIV RNA Level (median copies/mL, IQR) 75 (IQR 75 to 5138) 75 (IQR 75 to 221) 0.07§
CD4 Count (median cell/mL, IQR) 384.5 (IQR 210.3 to
618.8)
477 (IQR 297.5 to
622.5)
0.30§
CD4 Count Nadir (median cell/mL, IQR) 96 (IQR 33.75 to
218)
128 (IQR 35.5 to
300)
0.33§
History of OI (n, %) 20 (53%) 43 (38%) 0.11‡
History of HAART use (n, %) 34 (90%) 94 (83%) 0.30‡
HAART Duration (median years, IQR) 5.68 (IQR 1.89 to
8.08)
5.79 (IQR 0.33 to
7.81)
0.52§
Current IVDU (n, %) 4 (11%) 3 (3%) 0.04‡
History of IVDU (n, %) 8 (21%) 19 (17%) 0.54‡
HCV Infection (n, %) 7 (18%) 29 (25%) 0.38‡
CAC detected (n, %) 21 (55%) 43 (38%) 0.09‡
Age- and Gender-adjusted CAC percentile
(median percentile, IQR)
44 (IQR 0 to 90) 0 (IQR 0 to 40) 0.01§
§Wilcox Rank-Sum Comparison P value
‡ Pearson’s χ2 Comparison P value
Abbreviations: Interquartile Range (IQR), Mitral Annular Calcification (MAC), Coronary Artery Disease
(CAD), Myocardial Infarction (MI), Human Immunodeficiency Virus (HIV), Human Immunodeficiency Virus
Ribonucleic Acid Level (HIV RNA), Cluster of Differentiation 4 cells (CD4), Opportunistic Infection (OI),
Highly Active Anti-Retroviral Therapy (HAART), Intravenous Drug-Use (IVDU), Hepatitis C Viral Infection
(HCV), Coronary Artery Calcification (CAC)
doi:10.1371/journal.pone.0130592.t002
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Fig 7). Using echocardiography, M-mode measurements of MAC in the parasternal long axis
views were significantly correlated with higher CAC composite scores (Spearman’s r 0.23,
p = 0.005) and higher age- and gender-adjusted CAC percentiles (Spearman’s r 0.29,
p = 0.001). In contrast, M-mode measurements of MAC performed in the apical four chamber
view did not correlate with CAC composite scores or age- and gender-adjusted CAC percen-
tiles (p = 1.0 and p = 0.84 respectively). After adjustment for HIV characteristics and tradi-
tional risk factors, the presence of MAC, prior CVD, older age and higher HIV RNA levels
were independently associated with higher age- and gender-adjusted CAC percentiles
(p< 0.05 for all).
Mortality Data
Over a median follow-up period of 8 years (IQR 7 to 8, 988 person-years), 11 subjects died
(1.11 per 100 person-years). Seven of the eleven subjects who died had CAC without MAC
(64%), two had MAC only (18%), and one had both MAC and CAC (9%). One of the eleven
subjects who died had neither CAC nor MAC (9%). Subjects with CAC had significantly higher
all-cause mortality compared to those without CAC, or compared to those with only MAC
Table 3. Baseline Characteristics—Subjects with CAC vs. those without CAC.
CAC (n = 64) No CAC (n = 88) P value
Age (median years, IQR) 53 (IQR 48 to 59) 46.5 (IQR 42 to 51) <0.0001§
Female (n, %) 5 (8%) 15 (17%) 0.23 ‡
Hypertension (n, %) 24 (38%) 32 (36%) 0.89 ‡
Dyslipidemia (n, %) 31 (48%) 22 (25%) 0.003 ‡
Diabetes Mellitus (n, %) 8 (13%) 7 (8%) 0.35 ‡
CAD (n, %) 10 (16%) 2 (2%) 0.003 ‡
History of MI (n, %) 4 (6%) 1 (1%) 0.08 ‡
Tobacco use (n, %) 39 (61%) 55 (63%) 0.85 ‡
Tobacco Pack-years (median Pack-years, IQR) 10 (IQR 0 to 23) 3.75 (IQR 0 to 20) 0.39§
Family History of CAD (n, %) 15 (23%) 18 (20%) 0.66 ‡
BMI (median kg/m2, IQR) 24.36 (IQR 22.56 to 28.91) 26.29 (IQR 23.95 to 29.53) 0.06§
HIV duration (median years since diagnosis, IQR) 16 (IQR 11 to 19) 15 (IQR 11 to 19) 0.45§
HIV RNA Level (median copies/mL, IQR) 75 (IQR 75 to 466) 75 (IQR 75 to 412) 0.55§
CD4 Count (median cell/mL, IQR) 476 (IQR 226.8 to 636.5) 456 (IQR 291 to 658) 0.99§
CD4 Count Nadir (median cell/mL, IQR) 128 (IQR 36 to 284) 110 (IQR 30 to 300) 0.99§
History of OI (n, %) 29 (45%) 34 (38%) 0.41 ‡
History of HAART use (n, %) 57 (89%) 71 (81%) 0.16 ‡
HAART Duration (median years, IQR) 5.84 (IQR 1.07 to 7.66) 5.65 (IQR 0.32 to 7.94) 0.57§
Current IVDU (n, %) 2 (3%) 5 (6%) 0.47 ‡
History of IVDU (n, %) 12 (19%) 15 (17%) 0.75 ‡
HCV Infection (n, %) 17 (27%) 19 (22%) 0.48 ‡
MAC detected (n, %) 21 (33%) 17 (19%) 0.09‡
§Wilcox Rank-Sum Comparison P value
‡ Pearson’s χ2 Comparison P value
Abbreviations: Interquartile Range (IQR), Coronary Artery Calcification (CAC), Coronary Artery Disease (CAD), Myocardial Infarction (MI), Human
Immunodeficiency Virus (HIV), Human Immunodeficiency Virus Ribonucleic Acid Level (HIV RNA), Cluster of Differentiation 4 cells (CD4), Opportunistic
Infection (OI), Highly Active Anti-Retroviral Therapy (HAART), Intravenous Drug-Use (IVDU), Hepatitis C Viral Infection (HCV), Mitral Annular Calcification
(MAC)
doi:10.1371/journal.pone.0130592.t003
MAC and CAC Are Associated with Mortality in HIV-Infected Individuals
PLOS ONE | DOI:10.1371/journal.pone.0130592 July 1, 2015 12 / 19
(2.88 per 100 person-years in the CAC group vs. 1.86 per 100 person-years in the MAC group
vs. 0.20 per 100 person-years in the control group, p = 0.01, Fig 8). The Harrel’s C-statistic for
predicting mortality was 0.66 for CAC alone and increased to 0.75 when MAC was added
(comparison p = 0.05). The causes of death were variable, and included cardiac (n = 2, 18%),
malignancy (n = 2, 18%), drug ingestion (n = 2, 18%), cirrhosis of the liver (n = 1, 9%), homi-
cide (n = 1, 9%) and unknown (n = 3, 27%). Both cardiac deaths were in patients who had
CAC on CT. We performed a sensitivity analysis and repeated our analysis after exclusion of
individuals with known CAD. The findings of our sensitivity analysis were consistent with our
findings in the entire cohort, namely, the Harrel’s C-statistic for predicting all-cause mortality
was 0.66 for CAC alone and increased to 0.78 when MAC was added (comparison p = 0.03).
Discussion
We demonstrate that MAC using echocardiography and CAC by CT scan are common among
an asymptomatic cohort of HIV-infected individuals. The majority of these subjects were on
anti-retroviral treatment and were virologically suppressed. The presence of CAC was associ-
ated with a significantly higher all-cause mortality rate among HIV-infected individuals when
compared to those without CAC. The presence of MAC and CAC further increased the predic-
tive value for all-cause mortality. To our knowledge this is one of the first reports to demon-
strate the clinical significance of detectable CAC using EBCT in the HIV-positive patient
population [33]. Our findings are consistent with previous studies of HIV-uninfected individu-
als which have demonstrated that the presence of CAC is predictive of major adverse cardiac
events and mortality in asymptomatic individuals [28–32,34–38]. Nasir et al. studied a cohort
Fig 7. HIV-infected individuals with MAC have a higher median age- and gender-adjusted CAC percentile compared to those without MAC.
Abbreviations: Coronary Artery Calcification (CAC), Mitral Annular Calcification (MAC), Interquartile Range (IQR).
doi:10.1371/journal.pone.0130592.g007
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of 44, 052 asymptomatic patients and found that individuals who had elevated CAC scores in
the absence of traditional cardiovascular risk factors had significantly higher mortality rates
than individuals with multiple risk factors but no CAC [28]. Of note, these patients were all
referred for CAC screening based on clinician referral, and thus, the results are likely not appli-
cable to the asymptomatic HIV-infected individuals we studied. Arad et al. followed 1,173
asymptomatic patients for an average of 19 months and found a consistent correlation between
CAC and severity of CAD [37]. These patients were self-referred and outcome results were
based largely on subject questionnaire response. Along with other studies, these findings have
led to the growing popularity of using EBCT for identifying the presence of CAC. EBCT has
now been incorporated into the current ACC/AHA guidelines to determine risk of future car-
diovascular events among individuals at intermediate risk for cardiovascular disease or with a
strong family history of cardiovascular disease [39]. While the utility of screening of all HIV
patients using CAC remains ambiguous, our study demonstrates that detectable CAC along
Fig 8. Kaplan Meier survival curve for subjects based on presence (+) or absence (-) of Coronary Artery Calcium, Mitral Annular Calcification.
Abbreviations: Coronary Artery Calcification (CAC), Mitral Annular Calcification (MAC).
doi:10.1371/journal.pone.0130592.g008
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with MAC may identify a subset of HIV-infected individuals at higher risk for all-cause
mortality.
There have been several studies which have examined the prevalence and severity of CAC in
the HIV-infected population, but these studies report very few clinical outcomes [13,40,41].
Mangili et al. performed a cross-sectional analysis of 327 HIV-infected individuals who had
undergone carotid artery intima-media thickness screening (cIMT) and CAC EBCT and found
that for men included in the study, age, apolipoprotein B level, and high-sensitivity C-reactive
protein level independently predicted CAC score. Age and glucose level independently pre-
dicted CAC score in women [40]. Guaraldi and colleagues performed a cross-sectional analysis
of 400 HIV-infected individuals who had undergone CAC EBCT and found that 40.5% of the
cohort had increased vascular age on EBCT, but again, no clinical outcomes were reported
[42]. A multi-variate analysis revealed that current CD4 count was the only predictor of
increased vascular age [13]. Fitch and colleagues found that HIV-infected individuals who had
the metabolic syndrome, as well as HIV-infected individuals who did not have the metabolic
syndrome, demonstrated an increased prevalence of calcified and non-calcified plaque seg-
ments on CAC EBCT when compared to non-infected controls. Recently, a large study from
the MultiCenter Aids Clinical cohort (MACS), demonstrated that HIV features were indepen-
dently associated with non-calcified plaque at baseline [43]. However, to our knowledge, none
of these prior studies correlated CAC or other findings with mortality or other clinical out-
comes in the setting of HIV infection.
The presence of MAC using echocardiography has not been previously described among
individuals with HIV. A study following elderly individuals without HIV for 16 years demon-
strated an independent association between MAC and incident cardiovascular disease and car-
diovascular mortality [20]. Atar and colleagues reported that more than 1/3 subjects who were
screened with TTE had evidence of MAC. In turn, the presence of MAC was associated with a
higher prevalence of coronary artery disease, left main disease, and triple vessel disease as
revealed by cardiac catheterization. The positive predictive value of MAC for severe coronary
artery disease was 92% [15]. While echocardiographic studies performed in modern HIV
cohorts have reported high rates of diastolic dysfunction and elevated pulmonary artery pres-
sures [44], our report is the first to evaluate MAC in the setting of HIV infection and to link
this echocardiographic finding to clinical outcomes along with CAC.
Cardiovascular disease is the second most common cause of non-AIDS deaths among indi-
viduals with HIV in the United States [45]. As the HIV patient population continues to age,
HIV-associated cardiovascular complications will become an increasingly significant health
issue. The risk for acute MI is more than doubled in the setting of HIV infection and this
increased risk persists among treated and suppressed HIV-infected individuals [10]. Our group
has previously described high rates of sudden cardiac death, one of the most deadliest manifes-
tations of cardiovascular disease, among individuals with HIV [12]. Although the heightened
risk of cardiovascular events and mortality in the HIV-population has been well studied, few
studies have explored the utility of non-invasive studies to identify individuals at risk. As such,
there is no consensus regarding the use of these non-invasive assessments of cardiovascular dis-
ease in HIV-infected subjects. Much of our current clinical practice is driven by extrapolation
of findings from studies of HIV-negative subjects. The results of this study suggest that EBCT
screening for CACmay be useful for identifying HIV-infected individuals at high risk for all-
cause mortality. Furthermore, the addition of the presence of MAC to CAC resulted in signifi-
cant improvement in the characteristics of the Harrel’s C-statistic for prediction of individuals
at the highest risk for death over the course of this study (988 person-years). When quantified,
MAC is typically labeled as mild, moderate or severe, and these gradations are highly subjective
and have sub-optimal inter-observer variability. Our study demonstrated a linear correlation
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between MAC when measured in the parasternal long axis view and CAC score, as well as age-
and gender-adjusted CAC percentile. This correlation did not hold when MAC was measured
in the apical four chamber view, which may be due to measuring technique or artifact when
measured in this view. These findings are relevant as they suggest there is a quantifiable rela-
tionship between MAC and CAC, and they have biological plausibility as calcification is likely a
systemic process affecting both the heart valves and coronaries at the same time.
Previous studies have also demonstrated that age- and gender-adjusted CAC percentile is
the preferred parameter for predicting cardiovascular and mortality outcomes using CAC-pro-
tocol EBCT data [34,35,38]. Population based studies have demonstrated the overall prevalence
of MAC to be roughly 13%44 and CAC to be between 40–60% in subjects with a mean age of
53 ± 11 years [34,37,46,47]. We found a similar prevalence of CAC in our HIV-infected individ-
uals along with a markedly higher prevalence of MAC despite the younger age of our cohort
(mean age 49.4 ± 0.7 years). Post and colleagues demonstrated coronary artery plaque, particu-
larly non-calcified plaque is more prevalent and extensive in HIV-infected men, independent of
CAD risk factors, and thus future studies will be needed to ascertain if non-calcified plaque may
be more predictive of events as compared to CAC in HIV-infected individuals. As our study
only examined coronary artery calcification, we were not able to evaluate non-calcified plaques.
The findings are consistent with previously proposed theories of an accelerated vascular
aging complex related to the HIV virus [13,48]. In this study, after adjustment for HIV charac-
teristics and traditional risk factors, including age, gender, tobacco use, hypertension, dyslipi-
demia, and diabetes mellitus, the presence of MAC, prior CVD, older age and higher HIV
RNA levels were independently associated with higher age- and gender-adjusted CAC percen-
tiles. While age is usually the strongest predictor of calcium, our findings suggest that uncon-
trolled HIV disease may also contribute to coronary calcification and thus increased
cardiovascular risk.
Limitations
There are several limitations to this study. Since this is a retrospective cohort, we cannot
assume or invoke causality for any of the associations that were found. Our study evaluated the
predictive value of baseline prevalent MAC and CAC upon mortality in HIV; future studies
which incorporate serial imaging will be needed to evaluate the impact of incidence of MAC or
CAC on mortality. The sample size was also small and may be under-powered to determine
differences in mortality outcomes, particularly cardiovascular death, as there were very few of
these events during the course of the study. This study was performed at a single center, thus,
the population studied may not be representative of the HIV-positive population as a whole.
Some of the variables studied, including tobacco use, pack-years, family history of coronary
artery disease and past or present injection drug use relied on subject self-report, and thus may
be susceptible to reporting bias; however it is unlikely that there was differential reporting bias
among those with and without CAC and/or MAC. As the baseline demographic variables and
clinical outcome variables (death) were obtained via query of existing databases, we were only
able to report variables which were available in the respective databases. Other outcomes such
as new cardiovascular or coronary events were not available at the time of query. Finally, the
Agatston scoring method for coronary artery calcification has several limitations, which have
been well documented. These include image noise and artifact influencing CAC score, the non-
linear increases in calcium score due to density numbers used to categorize pixel intensity, and
the inaccuracies in the Agatston score, which may under- or over-estimate the true volume of
calcium in a given lesion [49].
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Conclusions
The current study demonstrates that 1) MAC and CAC among HIV-infected individuals are
common, 2) the presence of both CAC and MAC identify HIV-positive patients at elevated
risk for all-cause mortality, 3) there is a significant association between mitral annular calcifica-
tion and age- and gender-adjusted coronary calcium percentile, and 4) traditional risk factors
along with HIV viral load are independently associated with CAC. Taken together, these find-
ings support the premise that HIV infection may play a role in accelerated vascular and cellular
aging and that presence of systemic calcium may identify HIV-infected individuals at high risk
for all-cause mortality. Further investigation is needed to determine whether modification of
cardiovascular risk factors and / or HIV disease activity can alter HIV-positive subject’s coro-
nary artery or mitral annular calcification profile.
Supporting Information
S1 Table. Microsoft Excel Database. Attached please find our anonymous primary dataset.
The most pertinent portions of this dataset include sheet 1, titled, “MAC HIV subjects, no con-
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grams and computed tomography scans as described in the methods section. Sheet 2 has more
detailed descriptions of the variables that were recorded as well as translation codes.
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